Richard B Gearry, Peter M Irving. Show Affiliations »
Abstract
Entities: Disease
Mesh： See more » AdalimumabAnti-Inflammatory Agents/administration & dosageAnti-Inflammatory Agents/economicsAnti-Inflammatory Agents/therapeutic useAntibodies, Monoclonal/administration & dosageAntibodies, Monoclonal/economicsAntibodies, Monoclonal/therapeutic useAntibodies, Monoclonal, HumanizedAsiaAustraliaColitis, Ulcerative/diagnosisColitis, Ulcerative/drug therapyColitis, Ulcerative/economicsColitis, Ulcerative/ethnologyCost-Benefit AnalysisCrohn Disease/diagnosisCrohn Disease/drug therapyCrohn Disease/economicsCrohn Disease/ethnologyDrug Administration ScheduleDrug CostsGastrointestinal Agents/administration & dosageGastrointestinal Agents/economicsGastrointestinal Agents/therapeutic useHealth Services AccessibilityHumansInfliximabPatient SelectionRemission InductionSeverity of Illness IndexTime FactorsTreatment Failure
Substances： See more » Anti-Inflammatory AgentsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedGastrointestinal AgentsInfliximabAdalimumab
Year: 2009 PMID： 19682189 DOI： 10.1111/j.1440-1746.2009.05896.x
Source DB: PubMed Journal: J Gastroenterol Hepatol ISSN： 0815-9319 Impact factor: 4.029